Baxter International (BAX) vs LeMaitre Vascular (LMAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Baxter International (BAX) has outperformed LeMaitre Vascular (LMAT) over the past year, gaining 5.1% versus a loss of 9.5%. Over five years, LMAT leads with a +48.6% price change compared with -70.0% for BAX. Baxter International is the larger company by market cap ($12.59 billion vs $1.85 billion), about 6.8 times the size, while LeMaitre Vascular is growing revenue faster (+13.5% vs +5.7%).
On valuation, Baxter International trades at a lower forward P/E (11.9x vs 25.4x for LeMaitre Vascular). LeMaitre Vascular offers the higher dividend yield (1.12% vs 0.82%). LeMaitre Vascular converts more of its revenue into profit, with a net margin of 23.1% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | LMAT |
|---|---|---|
| Share price | $24.35 | $80.69 |
| Market cap | $12.59B | $1.85B |
| 1-day change | +1.88% | +1.32% |
| YTD return | +25.07% | -1.80% |
| 1-year return | +5.05% | -9.54% |
| 5-year return | -70.01% | +48.64% |
| P/E ratio (TTM) | — | 28.31 |
| Forward P/E | 11.94 | 25.38 |
| EPS (TTM) | $-1.88 | $2.85 |
| Dividend yield | 0.82% | 1.12% |
| Annual dividend | $0.20 | $0.90 |
| Revenue (latest FY) | $11.24B | $249.60M |
| Revenue growth (YoY) | +5.72% | +13.53% |
| Net income (latest FY) | $-957.00M | $57.73M |
| Gross margin | 30.05% | 71.53% |
| Operating margin | -2.74% | 27.21% |
| Net margin | -8.51% | 23.13% |
| 52-week high | $30.00 | $118.01 |
| 52-week low | $15.73 | $78.22 |
| Distance from 52-week high | -18.83% | -31.62% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +14.66% | +32.61% |
| Average volume | 6.66M | 330.14K |
| Shares outstanding | 517.00M | 22.87M |
| Employees | 37,500 | 646 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Baxter International is about 6.8 times larger than LeMaitre Vascular by market value ($12.59B vs $1.85B).
- BAX has outperformed LMAT by 14.6 percentage points over the past year.
- LeMaitre Vascular is more profitable, keeping 23.1 cents of every revenue dollar as net income versus -8.5 cents for Baxter International.
- LeMaitre Vascular grew revenue faster in its latest fiscal year (+13.53% vs +5.72%).
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Health Care · Medical/Dental Instruments · 37,500 employees
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
BAX vs LMAT FAQ
Which is bigger, Baxter International or LeMaitre Vascular?
Baxter International (BAX) is larger, with a market capitalization of $12.59B compared with $1.85B for LeMaitre Vascular (LMAT).
Which stock has performed better over the past year, BAX or LMAT?
BAX returned +5.05% over the past 12 months, compared with -9.54% for LMAT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or LeMaitre Vascular?
LeMaitre Vascular has the higher yield at 1.12%, compared with 0.82% for Baxter International.
Are Baxter International and LeMaitre Vascular in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.